Evaluation of Iron overload in pediatric patients with beta thalassemia major

Bakheet, Marina Samir; Abd EL-Halim, Sahar Salah; Morgan, Dalia Saber; Abd Elkareem, Rehab Muhammad

doi:10.21608/ejmr.2023.221945.1417

Evaluation of Iron overload in pediatric patients with beta thalassemia major

Document Type : Original Article

Authors

¹ Pediatric Medicine department, Faculty of Medicine, Beni-Suef University

² Clinical and chemical pathology department, Faculty of Medicine, Beni-Suef University

10.21608/ejmr.2023.221945.1417

Abstract

Background: Thalassemia is the commonest hereditary hemolytic anemia in Egypt. It was estimated that 1000 per 1, 5 Million live births per year are born with thalassemia. Iron overload is a major complication of repeated blood transfusion in patients with thalassemia. Objectives: This study was conducted to evaluate Iron overload in pediatric patients with beta thalassemia major and comparing this with the control serum level. Methods: The study included fourty five patients with ß- thalassemia major with fourty five age and sex matched controls. Patients were selected from the outpatient's clinics of the Pediatric Hematology unit and the inpatients of Pediatric department. Patients and control were subjected to clinical evaluation and complete blood count along with serum ferritin (using the ELISA technique). Results: serum ferritin level was significantly higher in patients with beta thalassemia major compared with controls. There was significant difference between both groups as regard , TIBC (µM), HbA2 level (%), HbA level (%), HbF level (%). Conclusion: We concluded that the serum levels of ferritin were significantly higher in patients with beta thalassemia major in comparison to control group.

Keywords

Main Subjects

Internal medicine ·

References

Origa R; (2017) Beta-thalassemia. Genetics in Medicine 19:609 – 619.
Hoffbrand A, Taher A, Cappellini M, (2012). How I treat transfusional iron overload. Blood. 120(18):3657 – 3669.
Almousawi AS, Sharba IR. (2019). Erythroferrone hormone a novel biomarker is associated with anemia and iron overload in beta thalassemia patients. In Journal of Physics: Conference Series. IOP Publishing, 1294(6):062045.
Kautz L, Jung G, Valore E, Rivella S, Nemeth E, Ganz T, (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46(7):678 – 684.
Harrison, C. (2019). First gene therapy for [beta]-thalassemia approved. Nature biotechnology, 37(10), 1102-1104.
Susanah, S, Rakhmilla, L. E, Ghozali, M, Trisaputra, J. O, Moestopo, O, Sribudiani, Y, et al. (2021). Iron Status in Newly Diagnosed β-Thalassemia Major: High Rate of Iron Status due to Erythropoiesis Drive. BioMed Research International, 2021.
El-Gamal, R. A. E. R, Abdel-Messih, I. Y, Habashy, D. M, Zaiema, S. E. G, & Pessar, S. A. (2020). Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia. Annals of Hematology, 99(1), 31-39.‏
Saad, H, Bahgat, S. M, El Dewy, DM, Galal, R. K. (2021). Erythroferrone Level in β-thalassemia Patients. Journal of Recent Advances in Medicine, 2(1), 1-9.
Ezzat, A. M, Abdelmotaleb, G. S, Shaheen, A. M, Ismail, Y. M, Diab, A. M. (2016). Peroxidative stress and antioxidant enzymes in children with β-thalassemia major. Medical Research Journal, 15(2), 57-62.
Pratummo, K, Jetsrisuparb, A, Fucharoen, S, Tripatara, A. (2014). Hepcidin expression from monocyte of splenectomized and non-
Mohapatro, M, Padhy, S, Patro, M. K, Sethi, R. K. (2017). Detection of haemoglobinopathies using haemoglobin electrophoresis in microcytic hypochromic anaemia in paediatric population of southern odisha. Journal of Evidence Based Medicine and Healthcare, 4, 653-60.